AI-generated summary
This review describes transcranial photobiomodulation, which applies low-intensity red or near-infrared light through the skull, for central nervous system disorders. The authors summarize its proposed mechanisms and recent preclinical and clinical advances in conditions such as ischemic stroke, traumatic brain injury, neurodegenerative diseases, epilepsy and depression. They call for more and larger studies to validate its wider application.
- Who or what was studied
- Central nervous system disorders, including ischemic stroke, traumatic brain injury, neurodegenerative diseases, epilepsy and depression, in preclinical and clinical studies
- Limits stated in the abstract
- The abstract states that more and larger studies are needed to validate transcranial photobiomodulation for central nervous system disorders.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Transcranial photobiomodulation, Adenosine triphosphate, Traumatic brain injury, Oxidative stress, Near-infrared, Brain injury, Inflammation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.